
May 21 (Reuters) - REPRONOVO:
ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced the successful closing of a $65 million Series A financing round.
The round was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Ventures, with strong syndicate support from Ysios Capital and ALSA Ventures.
ReproNovo is headquartered in Lausanne and has teams in Copenhagen and Barcelona